Bob M. Olsson

Moelndal, O, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Comparing progression biomarkers in clinical trials of early Alzheimer's disease.

Comparing progression biomarkers in clinical trials of early Alzheimer's disease.

Journal: Annals of clinical and translational neurology
Published: May 27, 2020

Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage.

Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage.

Journal: Journal of Alzheimer's disease : JAD
Published: March 17, 2020

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases.

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases.

Journal: Acta neurologica Scandinavica
Published: March 21, 2019

NFL is a marker of treatment response in children with SMA treated with nusinersen.

NFL is a marker of treatment response in children with SMA treated with nusinersen.

Journal: Journal of neurology
Published: January 07, 2019

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

Journal: JAMA neurology
Published: December 04, 2018

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 12, 2018

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Journal: Acta neuropathologica
Published: December 13, 2017

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.

Journal: Expert review of neurotherapeutics
Published: June 13, 2017

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.

Journal: Alzheimer's research & therapy
Published: June 12, 2017

Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.

Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.

Journal: Annals of hematology
Published: June 10, 2017

The clinical value of fluid biomarkers for dementia diagnosis - Authors' reply.

The clinical value of fluid biomarkers for dementia diagnosis - Authors' reply.

Journal: The Lancet. Neurology
Published: July 20, 2016

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.

Journal: European journal of neurology
Published: February 14, 2016
Showing 1-12 of 52

Last Updated: 09/26/2026